CytRx Corporation
11726 San Vicente Boulevard
Suite 650
Los Angeles,
CA 90049
United States - Map
Phone: 310-826-5648
Fax: 310-826-6139
Web Site: http://www.cytrx.com
| CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology. The company was founded in 1985 and is headquartered in Los Angeles, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Steven A. Kriegsman , 66
Chief Exec. Officer, Pres |
N/A
| N/A | Dr. Joseph Rubinfeld Ph.D., 76
Chief Scientific Advisor, Independent Director and Member of Scientific Advisory Board |
$
74.00K | N/A | Mr. Benjamin S. Levin , 33
VP of Legal Affairs, Corp. Sec. and Gen. Counsel |
N/A
| N/A | Dr. Chung Ng Shi Ph.D., 54
Sr. VP of R&D |
$
316.00K | N/A | Dr. Jack R. Barber Ph.D., 54
Chief Scientific Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.03 (2.78%) 
Profile
